1. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA 2018;320:1360–1372.

2. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294–2300.

3. Turesson C. Comorbidity in rheumatoid arthritis. Swiss Med Wkly 2016;146:w14290.

4. Jani M, Barton A, Hyrich K. Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification? Curr Opin Rheumatol 2019;31:285–292.

5. Ratnatunga CN, Lutzky VP, Kupz A, et al. The rise of non-tuberculosis mycobacterial lung disease. Front Immunol 2020;11:303.

6. Lim DH, Kim YG, Shim TS, et al. Nontuberculous mycobacterial infection in rheumatoid arthritis patients: a single-center experience in South Korea. Korean J Intern Med 2017;32:1090–1097.

7. Cowman S, van Ingen J, Griffith DE, Loebinger MR. Non-tuberculous mycobacterial pulmonary disease. Eur Respir J 2019;54:1900250.

8. Yamakawa H, Takayanagi N, Miyahara Y, et al. Prognostic factors and radiographic outcomes of nontuberculous mycobacterial lung disease in rheumatoid arthritis. J Rheumatol 2013;40:1307–1315.

9. Yoo JW, Jo KW, Kang BH, et al. Mycobacterial diseases developed during anti-tumour necrosis factor-α therapy. Eur Respir J 2014;44:1289–1295.

10. Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012;185:575–583.

11. Mori S, Koga Y, Nakamura K, et al. Mortality in rheumatoid arthritis patients with pulmonary nontuberculous mycobacterial disease: a retrospective cohort study. PLoS One 2020;15:e0243110.

12. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–324.

13. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580–1588.

14. Griffith DE, Aksamit T, Brown-Elliott BA, et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367–416.

15. Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis 2020;71:e1–e36.

16. Hashemi R, Majidi A, Motamed H, Amini A, Najari F, Tabatabaey A. Erythrocyte sedimentation rate measurement using as a rapid alternative to the Westergren method. Emerg (Tehran) 2015;3:50–53.

17. Yamakawa H, Takayanagi N, Ishiguro T, Kanauchi T, Hoshi T, Sugita Y. Clinical investigation of nontuberculous mycobacterial lung disease in Japanese patients with rheumatoid arthritis receiving biologic therapy. J Rheumatol 2013;40:1994–2000.

18. Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of Interstitial Lung Disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010;62:1583–1591.

19. Yang JA, Moon J, Chang SH, et al. AB0356 comparison of the clinical characteristics of rheumatoid arthritis patients with and without interstitial lung disease. Ann Rheum Dis 2015;74(Suppl 2):1012.

20. Caplan L, Wolfe F, Russell AS, Michaud K. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 2007;34:696–705.

21. Liao TL, Lin CF, Chen YM, Liu HJ, Chen DY. Risk factors and outcomes of nontuberculous mycobacterial disease among rheumatoid arthritis patients: a case-control study in a TB endemic area. Sci Rep 2016;6:29443.

22. Kotilainen H, Valtonen V, Tukiainen P, Poussa T, Eskola J, Järvinen A. Clinical symptoms and survival in non-smoking and smoking HIV-negative patients with non-tuberculous mycobacterial isolation. Scand J Infect Dis 2011;43:188–196.

23. Erasmus JJ, McAdams HP, Farrell MA, Patz EF Jr. Pulmonary nontuberculous mycobacterial infection: radiologic manifestations. Radiographics 1999;19:1487–1505.

24. Winthrop KL, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013;72:37–42.

25. Brode SK, Jamieson FB, Ng R, et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax 2015;70:677–682.

26. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261–1265.

27. Kourbeti IS, Ziakas PD, Mylonakis E. Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis 2014;58:1649–1657.

28. Takei H, Nishina N, Namkoong H, et al. Rheumatoid arthritis with nontuberculous mycobacterial pulmonary disease: a retrospective, single-centre cohort study. Mod Rheumatol 2022;32:534–540.

29. Kim Y, Chun P. Analysis of prescription patterns for rheumatoid arthritis in Korea. Yakhak Hoeji 2019;63:341–350.

30. Büyükcavlak M, Duman I, Eryavuz OD, Ünlü A, Duman A. Effects of artemisinin and hydroxychloroquine on cytokines in experimental sepsis. Trop Biomed 2022;39:547–551.

31. Majzoobi MM, Hashemi SH, Mamani M, Keramat F, Poorolajal J, Ghasemi Basir HR. Effect of hydroxychloroquine on treatment and recurrence of acute brucellosis: a single-blind, randomized clinical trial. Int J Antimicrob Agents 2018;51:365–369.

32. Teh CL, Wan SA, Ling GR. Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality. Clin Rheumatol 2018;37:2081–2086.

33. Urabe N, Sakamoto S, Ito A, et al. Bronchial brushing and diagnosis of pulmonary nontuberculous mycobacteria infection. Respiration 2021;100:877–885.

34. Watanabe K, Shinkai M, Shinoda M, Kaneko T. Bronchial wash culture is less valuable in patients suspected to have nontuberculous mycobacteria lung disease for bilateral bronchiectasis with nodules. Int J Mycobacteriol 2018;7:178–182.